The Bovalto range has been specially developed to provide prime-boost capability, meaning that, together, the vaccines provide a flexible protocol. Used sequentially as part of a farm-specific vaccine plan they can provide rapid protection of young calves, followed by a proven extended duration of immunity when an initial shot of Bovalto Respi Intranasal is followed by a course of a Bovalto Respi Injectable vaccine.
As shown in the January 2022 summary of product characteristics, Bovalto Respi Intranasal is the only intransasal vaccine whose efficacy against both RSV and PI3 is unaffected by maternally derived antibodies. It is delivered as a single dose, from 10 days of age and provides immunity for 12 weeks, from 10 days after vaccination.
Bovalto Respi 3 and 4 provide six months’ protection, starting from three weeks after the initial course of two injections (Summary of product characteristics, 2022). In addition to providing protection against PI3 and RSV, both also protect against Mannheimia haemolytica. Bovalto Respi 4 also protects against BVD, which is important for farms buying in youngstock with unknown BVD status.
To accompany the range, the Bovalto Respisafe applicator has been designed to overcome the challenges of effective vaccine delivery to the nasal passages and to ensure vaccination is a comfortable process for both farmer and calf. The administration pack features a high quality vaccinator, a set of nozzles that delivers the vaccine at the optimum droplet size and a soft Bovalto Respisafe applicator which fits against the calf’s nostril.
For further information vets should contact their Boehringer Ingelheim Animal Health ruminant specialist or the technical help desk 01344 746957 (UK) and 01 291 3985 (Ireland).
